CO2024011162A2 - Inhibidores de nlrp3 - Google Patents
Inhibidores de nlrp3Info
- Publication number
- CO2024011162A2 CO2024011162A2 CONC2024/0011162A CO2024011162A CO2024011162A2 CO 2024011162 A2 CO2024011162 A2 CO 2024011162A2 CO 2024011162 A CO2024011162 A CO 2024011162A CO 2024011162 A2 CO2024011162 A2 CO 2024011162A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- nlrp3
- inhibitors
- disorders
- nlrp3 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311463P | 2022-02-18 | 2022-02-18 | |
| PCT/US2022/075421 WO2023028534A1 (en) | 2021-08-25 | 2022-08-24 | Inhibitors of nlrp3 |
| PCT/US2023/062771 WO2023159148A2 (en) | 2022-02-18 | 2023-02-16 | Inhibitors of nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024011162A2 true CO2024011162A2 (es) | 2024-12-09 |
Family
ID=87579158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0011162A CO2024011162A2 (es) | 2022-02-18 | 2024-08-16 | Inhibidores de nlrp3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250179078A1 (enExample) |
| EP (1) | EP4479045A4 (enExample) |
| JP (1) | JP2025509088A (enExample) |
| KR (1) | KR20240164495A (enExample) |
| CN (2) | CN118302417A (enExample) |
| AU (1) | AU2023221847A1 (enExample) |
| CA (1) | CA3243870A1 (enExample) |
| CL (1) | CL2024002455A1 (enExample) |
| CO (1) | CO2024011162A2 (enExample) |
| CR (1) | CR20240345A (enExample) |
| IL (1) | IL315027A (enExample) |
| MX (1) | MX2024010092A (enExample) |
| PE (1) | PE20250604A1 (enExample) |
| WO (1) | WO2023159148A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| JP2026508178A (ja) | 2023-02-14 | 2026-03-10 | シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー， リミテッド | Ｎｌｒｐ３を阻害する化合物及びその製造方法と応用 |
| TW202535370A (zh) * | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026067767A1 (zh) * | 2024-09-30 | 2026-04-02 | 普罗思特(南京)生物科技有限公司 | 取代的哒嗪衍生物及其应用 |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583208B (zh) * | 2012-05-16 | 2016-09-28 | 杨森制药公司 | 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物 |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| CA3174837A1 (en) * | 2020-04-15 | 2021-10-21 | Daniel Oehlrich | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| IL310992A (en) * | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
-
2022
- 2022-08-24 CN CN202280071320.9A patent/CN118302417A/zh active Pending
-
2023
- 2023-02-16 IL IL315027A patent/IL315027A/en unknown
- 2023-02-16 CR CR20240345A patent/CR20240345A/es unknown
- 2023-02-16 CN CN202380034776.2A patent/CN119212699A/zh active Pending
- 2023-02-16 JP JP2024548556A patent/JP2025509088A/ja active Pending
- 2023-02-16 PE PE2024001809A patent/PE20250604A1/es unknown
- 2023-02-16 EP EP23757102.1A patent/EP4479045A4/en active Pending
- 2023-02-16 WO PCT/US2023/062771 patent/WO2023159148A2/en not_active Ceased
- 2023-02-16 US US18/839,229 patent/US20250179078A1/en active Pending
- 2023-02-16 AU AU2023221847A patent/AU2023221847A1/en active Pending
- 2023-02-16 KR KR1020247027203A patent/KR20240164495A/ko active Pending
- 2023-02-16 CA CA3243870A patent/CA3243870A1/en active Pending
-
2024
- 2024-08-15 CL CL2024002455A patent/CL2024002455A1/es unknown
- 2024-08-16 CO CONC2024/0011162A patent/CO2024011162A2/es unknown
- 2024-08-16 MX MX2024010092A patent/MX2024010092A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119212699A (zh) | 2024-12-27 |
| CA3243870A1 (en) | 2023-08-24 |
| WO2023159148A3 (en) | 2023-10-05 |
| AU2023221847A1 (en) | 2024-09-05 |
| CN118302417A (zh) | 2024-07-05 |
| US20250179078A1 (en) | 2025-06-05 |
| PE20250604A1 (es) | 2025-02-26 |
| WO2023159148A2 (en) | 2023-08-24 |
| MX2024010092A (es) | 2024-12-06 |
| CR20240345A (es) | 2024-09-16 |
| IL315027A (en) | 2024-10-01 |
| EP4479045A2 (en) | 2024-12-25 |
| EP4479045A4 (en) | 2026-03-04 |
| JP2025509088A (ja) | 2025-04-11 |
| CL2024002455A1 (es) | 2025-01-17 |
| KR20240164495A (ko) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002455A1 (es) | Inhibidores de nlrp3 | |
| ECSP24014832A (es) | Inhibidores de nlrp3 | |
| CL2021000191A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| CR20210552A (es) | Inhibidores del inflamasoma nlrp3 | |
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| MX2025002086A (es) | Inhibidores novedosos de inflamasoma nlrp3 | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2017014621A (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma. | |
| DOP2025000013A (es) | Inhibidores de inflamasoma nlrp3 | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| CR20230256A (es) | Compuestos farmacéuticos | |
| MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
| UY39484A (es) | Inhibidores de interleucina-17 | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CO2022014886A2 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 | |
| ECSP21062210A (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| CO2022012880A2 (es) | Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| UY38550A (es) | Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados | |
| AR134411A1 (es) | Compuestos de uracilo |